Augmedix, Inc. (NASDAQ:AUGX) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET

Company Participants

Ji-Yon Yi - Gilmartin Group LLC

Manny Krakaris - Chief Executive Officer

Paul Ginocchio - Chief Financial Officer

Conference Call Participants

Ryan Daniels - William Blair

Marc Wiesenberger - B. Riley Securities

Charlie Montang - Lake Street Capital Markets, LLC

Allen Klee - Maxim Group

Operator

Greetings and welcome to Augmedix, Inc. Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host Ji-Yon Yi, Investor Relations. Thank you. You may begin.

Ji-Yon Yi

Thank you, and thank you all for participating in today’s call. Joining me are Manny Krakaris, Chief Executive Officer; and Paul Ginocchio, Chief Financial Officer. Earlier today, Augmedix released financial results for the quarter ended September 30, 2022. A copy of the press release is available on the company’s Web site.

Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance, are forward-looking statements.

These forward-looking statements are based upon our current estimates and various assumptions and involve material risks and uncertainties that could cause actual results or events to materially defer from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors and management discussion and analysis of financial condition and results of operations in our most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, and similar disclosures and subsequent reports filed with the SEC.

Also during our call today, we may discuss non-GAAP financial measures which adjust our GAAP results to [indiscernible] impact certain items. You will find additional information regarding these non-GAAP financial measures and a reconciliation of these non-GAAP to GAAP measures in today’s financial results press release.

This conference call contains time sensitive information and is accurate only as of the live broadcast today, November 14, 2022. Augmedix disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.